Akebia (AKBA) Q3 2026 Earnings Call Transcript

Akebia reported Q3 2026 revenue of $36.9 million, down from $58.8 million a year earlier, and a $14.4 million net loss versus $0.5 million of net income; Auryxia revenue fell to $20 million from $42.5 million amid generic competition. Vafseo revenue rose 3% year over year to $14.8 million, while management estimated end-user demand of $19 million–$20 million and active patients grew 140% to about 11,500, though inventory drawdowns and slower large-provider adoption weigh on the transition ahead of the Jan. 1, 2027 TDAPA expiration. Management expects Vafseo’s annual cost to be $1,000–$1,500 in 2027 and cited VOICE data showing 10% fewer hospitalizations versus ESAs; the company ended September with $159.3 million in cash and expects its current resources to fund its operating plan for at least two years.

Analysis

The key underwriting issue is whether clinical differentiation can overcome the dialysis market’s procurement incentives. Lower hospital use could benefit providers that bear hospitalization costs, but that value may not accrue to the teams negotiating drug acquisition prices; declining ESA prices further tighten Vafseo’s price ceiling. VOICE is therefore a potential adoption catalyst, not yet proof that providers will convert patients at scale. The hospitalization economics also remain company-presented analysis, and should be tested against provider behavior and subsequent utilization data.

Reported revenue is particularly noisy through the TDAPA transition: inventory reductions can obscure patient growth, while post-TDAPA pricing and lower-than-modeled dosing/compliance may constrain revenue per patient. The more useful signals are end-user demand, active patients, and disclosed uptake at DaVita and Fresenius. DaVita’s requested contract extension is encouraging but not equivalent to a committed rollout; Fresenius’ slower decision process extends the adoption timeline. Auryxia’s generic-driven erosion compounds the commercial transition and increases the importance of disciplined spending and successful debt refinancing. The CCO’s departure during contract negotiations adds execution risk, even with consulting support.

Near term, expect headline revenue volatility and possible pressure as inventory resets. Over 1–3 months, watch for post-TDAPA contract terms, Q4 demand versus shipments, and evidence of LDO implementation. Over 6–18 months, sustained large-provider adoption and full VOCAL analyses—including any regulatory relevance for three-times-weekly dosing—could change the growth case. The contrarian opportunity is that a slow launch may understate the value of physician overlap and clinical evidence; the counterpoint is that projected standard-of-care penetration assumes a major behavior change in a price-sensitive bundled market.

Key Decisions for Investors

• Do not read Q3 product revenue as a clean demand signal. Track active patients and end-user demand against shipments through the inventory reset; a widening gap or falling patient counts would falsify the near-term growth thesis.
• Keep AKBA neutral-to-underweight through the transition rather than buying on the contract-extension headline. Reassess after evidence of actual DaVita rollout and disclosed post-TDAPA economics; verify contract duration, pricing, and volume commitments before underwriting a ramp.
• Treat VOICE/VOCAL as catalysts, not established commercial proof. Upgrade only if large-provider adoption accelerates and utilization translates into durable demand; monitor full VOCAL data and any regulatory filing or label decision.
• Stress-test liquidity using the Auryxia decline, post-TDAPA Vafseo pricing, operating cash burn, and term-loan refinancing terms. A refinancing setback, renewed ATM issuance, or further expense reductions that impair launch execution would argue for avoiding or hedging exposure.